Aptorum Group Limited Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
Aptorum Group (NASDAQ: APM) has received a notification from Nasdaq Stock Market on April 15, 2025, regarding non-compliance with the minimum bid price requirement of $1 per share under Nasdaq Listing Rule 5550(a)(2).
The company has been granted a 180-calendar-day grace period until October 14, 2025, to regain compliance with the listing requirements. During this period, the trading of APM shares on Nasdaq will continue unaffected.
To address this situation, Aptorum Group is evaluating various options, including the possibility of implementing a reverse stock split. The biotechnology company has expressed its commitment to maintaining its Nasdaq listing and will pursue necessary measures to achieve compliance within the specified timeframe.
Aptorum Group (NASDAQ: APM) ha ricevuto una comunicazione dal Nasdaq Stock Market il 15 aprile 2025 riguardo al mancato rispetto del requisito minimo del prezzo di offerta di 1 dollaro per azione previsto dalla Regola di quotazione Nasdaq 5550(a)(2).
Alla società è stato concesso un periodo di grazia di 180 giorni di calendario fino al 14 ottobre 2025 per tornare a rispettare i requisiti di quotazione. Durante questo periodo, le azioni APM continueranno a essere negoziate sul Nasdaq senza interruzioni.
Per affrontare questa situazione, Aptorum Group sta valutando diverse opzioni, incluso il possibile ricorso a uno split azionario inverso. L'azienda biotecnologica ha ribadito il proprio impegno a mantenere la quotazione sul Nasdaq e adotterà le misure necessarie per raggiungere la conformità entro i termini indicati.
Aptorum Group (NASDAQ: APM) recibió una notificación del Nasdaq Stock Market el 15 de abril de 2025 sobre el incumplimiento del requisito mínimo de precio de oferta de 1 dólar por acción, según la Norma de Listado Nasdaq 5550(a)(2).
La empresa ha recibido un período de gracia de 180 días naturales hasta el 14 de octubre de 2025 para volver a cumplir con los requisitos de cotización. Durante este tiempo, la negociación de las acciones de APM en Nasdaq continuará sin interrupciones.
Para abordar esta situación, Aptorum Group está evaluando varias opciones, incluida la posibilidad de implementar una consolidación inversa de acciones. La compañía biotecnológica ha manifestado su compromiso de mantener su cotización en Nasdaq y tomará las medidas necesarias para cumplir con los requisitos dentro del plazo establecido.
Aptorum Group (NASDAQ: APM)는 2025년 4월 15일 나스닥 증권거래소로부터 주당 최소 입찰가 1달러 요건을 충족하지 못했다는 통지를 받았습니다. 이는 나스닥 상장 규칙 5550(a)(2)에 따른 것입니다.
회사는 상장 요건을 다시 충족하기 위해 2025년 10월 14일까지 180일간의 유예 기간을 부여받았습니다. 이 기간 동안 APM 주식의 나스닥 거래는 영향을 받지 않고 계속됩니다.
이 상황을 해결하기 위해 Aptorum Group은 역병합 주식 분할 시행 가능성을 포함한 여러 방안을 검토 중입니다. 이 생명공학 회사는 나스닥 상장을 유지하겠다는 의지를 표명했으며, 지정된 기간 내에 규정 준수를 달성하기 위한 필요한 조치를 취할 것입니다.
Aptorum Group (NASDAQ : APM) a reçu une notification du Nasdaq Stock Market le 15 avril 2025 concernant la non-conformité à l'exigence de prix d'offre minimum de 1 dollar par action selon la règle de cotation Nasdaq 5550(a)(2).
La société bénéficie d'une période de grâce de 180 jours calendaires jusqu'au 14 octobre 2025 pour se conformer à nouveau aux exigences de cotation. Pendant cette période, la négociation des actions APM sur le Nasdaq se poursuivra sans interruption.
Pour remédier à cette situation, Aptorum Group étudie plusieurs options, y compris la possibilité de mettre en œuvre un regroupement d'actions inversé. La société de biotechnologie a réaffirmé son engagement à maintenir sa cotation au Nasdaq et prendra les mesures nécessaires pour respecter les exigences dans le délai imparti.
Aptorum Group (NASDAQ: APM) erhielt am 15. April 2025 eine Mitteilung von der Nasdaq Stock Market über die Nichteinhaltung der Mindestgebotspreisanforderung von 1 US-Dollar pro Aktie gemäß der Nasdaq-Listenregel 5550(a)(2).
Dem Unternehmen wurde eine kulante Frist von 180 Kalendertagen bis zum 14. Oktober 2025 eingeräumt, um die Anforderungen für die Notierung wieder zu erfüllen. Während dieses Zeitraums wird der Handel mit APM-Aktien an der Nasdaq unbeeinträchtigt fortgesetzt.
Um diese Situation zu bewältigen, prüft Aptorum Group verschiedene Optionen, einschließlich der Möglichkeit einer Aktienzusammenlegung. Das Biotechnologieunternehmen hat sein Engagement zur Aufrechterhaltung der Nasdaq-Notierung bekräftigt und wird die notwendigen Maßnahmen ergreifen, um die Einhaltung innerhalb des festgelegten Zeitrahmens zu erreichen.
- 180-day grace period granted to regain compliance
- Trading continues unaffected during compliance period
- Stock price has fallen below $1, triggering Nasdaq minimum bid price compliance issues
- Potential reverse stock split may be necessary to maintain listing
- Risk of delisting from Nasdaq if compliance is not achieved by October 14, 2025
Hong Kong, April 16, 2025 (GLOBE NEWSWIRE) -- Aptorum Group Limited (NASDAQ: APM), a leading Biotechnology company, today announced that it has received a notification from the Nasdaq Stock Market LLC dated 15 April 2025 regarding non-compliance with the minimum bid price requirement of
The notification does not immediately affect the listing or trading of the company’s shares on Nasdaq. Aptorum Group Limited has been granted a 180-calendar-day grace period, until 14 October 2025, to regain compliance with the continued listing requirements.
During this period, Aptorum Group Limited intends to evaluate all available options to restore compliance, including, if necessary, a reverse stock split. The company is committed to maintaining its Nasdaq listing and will take all reasonable measures to achieve compliance within the stipulated time frame.
About Aptorum Group Limited
Aptorum Group Limited is a pharmaceutical company, which engages in the discovery, development, and commercializing of therapeutic assets to treat diseases with unmet medical needs.
Forward-Looking Statements
This press release contains forward-looking statements that involve risks and uncertainties. These statements reflect the company’s current expectations and projections about future events and are based on assumptions. Actual results may differ materially from those projected.
For further information, please contact: investor.relations@aptorumgroup.com
FAQ
What is the deadline for Aptorum Group (APM) to regain Nasdaq compliance?
What is the minimum share price requirement that APM needs to meet for Nasdaq compliance?
Will APM stock continue trading on Nasdaq during the compliance period?
What solutions is Aptorum Group (APM) considering to address the Nasdaq compliance issue?
